OneSource Specialty Pharma shares jump 14% after Q2 results; recover 50% from recent lows

What happened

OneSource Specialty Pharma shares jumped nearly 14% on October 27 to a three-week high of Rs.1,589. Q2 revenue was Rs.516.2 crore, up 37% year-on-year, and adjusted profit after tax was Rs.93.7 crore.

Confirmed

Global impact / market context

Faster revenue and profit growth can make investors more willing to pay a higher price for each rupee of earnings. New drug-device combination capacity and service agreements support more future sales volume, which may lift profit if costs grow more slowly than revenue.

Analyst inference

The stock recovered about 50% from recent lows, showing investor views improved sharply after results. Strong sequential growth across all businesses and 12 launches suggest the company is adding products and customers, which can support demand for its shares.

Analyst inference

What to watch

1. The company cited its second commercial cartridge line and said the second half will see new launches and a significant ramp-up in commercial volumes, which means higher production and sales are planned. Confirmed
2. Watch whether new drug-device combination capacity and master services agreements turn into sustained revenue growth, because these were named as drivers of the latest quarter. Proposed
3. Monitor whether operating leverage continues to widen profit per sale, since EBITDA, which means earnings before interest, tax, depreciation and amortisation, rose faster than revenue; if cost growth speeds up, the recent profit improvement may slow. Analyst inference

Evidence

• Original source link unavailable